首页> 美国卫生研究院文献>Molecules >Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes
【2h】

Low-Molecular-Weight Heparins: Reduced Size Particulate Systems for Improved Therapeutic Outcomes

机译:低分子肝素:减小粒径的颗粒系统可改善治疗效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

A wide range of diseases have been treated using low-molecular-weight heparins (LMWHs), the drug of choice for anticoagulation. Owing to their better pharmacokinetic features compared to those of unfractionated heparin (uFH), several systems incorporating LMWHs have been investigated to deliver and improve their therapeutic outcomes, especially through development of their micro- and nano-particles. This review article describes current perspectives on the fabrication, characterization, and application of LMWHs-loaded micro- and nano-particles to achieve ameliorated bioavailability. The valuable applications of LMWH will continue to encourage researchers to identify efficient delivery systems that have specific release characteristics and ameliorated bioavailability, overcoming the challenges presented by biological obstructions and the physicochemical properties of LMWHs.
机译:低分子量肝素(LMWHs)是抗凝治疗的首选药物,已经治疗了多种疾病。由于与未分级肝素(uFH)相比,它们具有更好的药代动力学特性,因此研究了几种掺入LMWH的系统来提供和改善其治疗效果,尤其是通过开发其微米和纳米颗粒。这篇综述文章介绍了有关制备,表征和应用载有LMWHs的微米和纳米颗粒以改善生物利用度的最新观点。 LMWH的有价值的应用将继续鼓励研究人员确定具有特定释放特性和改善的生物利用度的有效传递系统,以克服LMWH的生物障碍和理化特性带来的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号